![](/imgs/covers/cr_cover.jpg)
|
Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482 EISSN: 0973-1482
Vol. 2, No. 3, 2006, pp. 144-146
|
Bioline Code: cr06033
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Journal of Cancer Research and Therapeutics, Vol. 2, No. 3, 2006, pp. 144-146
en |
Brief Communications-Trastuzumab: Is the new evidence revolutionary?
Munshi Anusheel, Singh Pritanjali, Jalali Rakesh
Abstract
A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.
Keywords
Trastuzumab, evidence, revolutionary
|
|
© Copyright 2006 Journal of Cancer Research and Therapeutics. Alternative site location: http://www.cancerjournal.net/
|
|